Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Status: RECRUITING

Eligibility Criteria

Age: 18 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * Participants enrolled in any Bayer-sponsored darolutamide feeder study at the time of study closure or primary completion, who are currently receiving darolutamide and are experiencing clinical benefit from treatment. * Participants who have not met any treatment discontinuation criteria in the feeder study protocol. * Willingness to continue practicing acceptable methods of birth control during the study.

Exclusion Criteria:

* Participant is unable to comply with the requirements of the study. * Negative benefit/ risk ratio as determined by the investigator. * Meet any criteria for treatment discontinuation of the feeder study the participant is coming from.

Conditions & Interventions

Interventions:
DRUG: Darolutamide (Nubeqa, BAY1841788)
Conditions:
Cancer
Keywords:
Roll-Over Study

More Information

Contact(s): Bayer Clinical Trials Contact - clinical-trials-contact@bayer.com
Principal Investigator: Paul, Asit, K.
Phase: PHASE3
IRB
Number: HM20024689
System ID: NCT04464226
